DRUG NEWS: More restrictions announced for acne drug

October 2005 
Volume 35  Number 10
Pages 30 - 30
  PDF Version Available!

 Under a new FDA program, everyone prescribing, taking, selling, or dispensing the acne drug isotretinoin (Accutane) will be required to enroll in a national registry by the end of the year. The iPLEDGE program is intended to ensure that health care professionals and patients understand the drug's serious risks—miscarriage, severe birth defects, depression, and suicidal thoughts—and take appropriate precautions, including avoiding pregnancy. Notorious for causing birth defects, isotretinoin has long been under fire by the March of Dimes and other advocacy groups who want it tightly controlled or taken off the market altogether.

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events